GP Program - Medication assisted treatment for opioid dependence
Prescribing medications for opioid dependence
South Australia has approximately 3000 people prescribed methadone liquid or buprenorphine with naloxone in film form (Suboxone®) to assist with the management of their opioid dependence.
Prescribing medications for opioid dependence is not complicated, however, there are some specific issues around the medications themselves, and about caring for people with
The GP Program provides support to prescribers of medication-assisted treatment for opioid dependence (
Further information and advice
- Drug and Alcohol Clinical Advisory Service (DACAS) telephone (08) 7087 1742.
Provides 24-hour clinical advice from senior medical staff, regarding
opioid dependentpatients and patients with other drug and alcohol relatedissues
- See the tabs below for information about MATOD Clinical Resources and Suboxone® prescribing.
- Visit GP Program - Accredited prescriber training and education for information about becoming a prescriber.
- Drugs of Dependence Unit telephone 1300 652 584 (office hours)
Provides advice on prescribing from a regulatory
- DASSA Central Service telephone (08) 7425 5000 (office hours). Ask for a senior medical officer.
- GP Program Project Officer: (08) 7425 5045
- Email: firstname.lastname@example.org
- Alcohol and Drug Information Service (ADIS) telephone 1300 13 1340
any day between 8.30am and
10pmfor information, counselling andreferral (South Australian callers - local call fee).
National Clinical Guidelines
The National Guidelines for Medication-Assisted Treatment of Opioid Dependence cover the use of methadone, buprenorphine, buprenorphine/naloxone and naltrexone all in one guideline. This document replaces previous full and abbreviated guidelines for these medications. Information on the assessment of opioid withdrawal, including the Subjective Opiate Withdrawal Scale (SOWS), the Objective Opiate Withdrawal Scale (OOWS) and the Clinical Opiate Withdrawal Scale (COWS) is included in Appendix 2.
Assessment and induction onto
- Maintenance Pharmacotherapy - Assessment and Initial Treatment (PDF 58KB)
This clinical form enables the recording of the assessment of a patient for
possiblecommencement of opioid pharmacotherapy.
- Initial Assessment Checklist (PDF 480KB) accredited prescribers
This document can be used as a checklist of steps to be taken when patients are inducted into medication-assisted treatment with methadone or buprenorphine formulations.
- Buprenorphine/naloxone (Suboxone®) Prescriber Initial Medical Assessment Checklist (PDF 612KB)
This document can be used as a checklist of steps to be taken when patients are being initiated into medication-assisted treatment with Suboxone®.
- Methadone and Buprenorphine Programs - Patient Agreement (DOC 29KB)
The ‘Essential information for patients commencing or recommencing on maintenance pharmacotherapy’ section must not be altered.
Your practice details need to be inserted and the details on the lower half of the form can be modified to fit
withyour practice requirement.
- Community pharmacy vacancy list
To obtain information about which community pharmacies have vacancies for patients and other details of community pharmacies involved in the program, please ring the Alcohol and Drug Information Service (ADIS) on 1300 13 1340.
- Maintenance Pharmacotherapies - Identification Form
This form can be used for making up an ID card for patients going to a community pharmacy.
Please contact the GP Program Project Officer for copies of this form on (08) 7425 5045 or email: email@example.com
- Letter of Introduction of Patient to Pharmacist (PDF 17KB)
This letter can be used after you have telephoned the pharmacist about a new patient. It is best to give the pharmacist as much clinical information as possible.
- Methadone Buprenorphine Not for Kids (PDF 67KB)
This brochure outlines what should be done if Methadone or Buprenorphine is taken by someone not prescribed the medication. Free copies of the brochure are available to prescriber holding authorities from the Alcohol and Drug Information Service (ADIS) on 1300 13 1340.
Drugs of Dependence - Medication Assisted Treatment for Opioid Dependence (
MATOD) forms and policy
- Authority Application MATOD Program (PDF 2.2MB)
To be used by both accredited and non-accredited prescribers.
To obtain the legally required Section 18A Controlled Substance Act 1984 (SA) authority to prescribe a drug of dependence for the treatment of opioid dependence, an initial application form must be filled in on both sides, signed by the prescriber and patient and faxed to the Drugs of Dependence Unit (DDU) at 1300 658 447. Then telephone DDU on 1300 652 584 (office hours) who will provide the
authoritynumber which can be written on the prescription. MATODunsupervised dosing policy (PDF 190KB) MATOD- split dosing methadone policy (PDF 135KB) MATODSerious Breaches Guideline (PDF 205KB)
- Drugs of Dependence Policy and Legal Obligations
- Medication Assisted Treatment for Opioid Dependence (
- Medication Assisted Treatment for Opioid Dependence (
MATOD) Suboxone Program
Management tools – related to
- Medications for Symptomatic Opiate Withdrawal (SOW) Management (PDF 52KB)
In many instances, withdrawal may need to be managed with symptomatic medication rather than with buprenorphine. This list outlines what is used currently at DASSA for symptomatic relief of opioid withdrawal. Of course, in most situations buprenorphine-assisted detox is preferable.
- Prescription Review (PDF 51KB)
This form is used for recording review consultations with patients established on opioid pharmacotherapy.
- Maintenance Pharmacotherapy - Stabilisation / Withdrawal (including Clinical Opiate Withdrawal Scale) (PDF 97KB)
This form is used in the first days of
stabilisationand includes a running sheet on one side, together with a COWS assessment tool for each day for recording the patient’s subjective assessment of withdrawal.
- Methadone —
drugto drug interactions (including QTc Prolongation) (DOC 52KB)
This information sheet provides information about drug-to-drug interactions include QTc prolongation, for health practitioners involved in patient care where methadone is prescribed. Please insert your practice details into the document.
- Urine drug screening: its use in determining patient progress (PDF 88KB)
Provides information on your
patientssubstance use relatedproblems.
- Benzodiazepine Dose Equivalents (PDF 187KB)
This list allows the clinician to convert doses among benzodiazepines.
- Opioid dose Equivalence: Calculation of oral Morphine Equivalent Daily Dose (oMEDD). Please note the caveats that accompany the table.
Table and full reference
isavailable at the Faculty of Pain Medicine ANZCA.
- Contact information for MATOD patients
You may wish to include this in your patient’s file, put a copy in your practice policy folder, and/or laminate a copy for your consulting room.
- Monitoring of patient prescriptions from other doctors (PDF 42KB)
It is important to be aware of other drugs the patient may be
usingwhen prescribing methadone or buprenorphine due to possible drug interactions. Patients may provide information about their other drug use along with Urine Drug Screens (UDS).
There are systems in place that may provide you with additional sources of information about your patient. Patients may provide more accurate information if they know that you can check the information they give you.
The systems listed in the attached document above appear to be extensive, however, once the initial paperwork has been completed, accessing the information is relatively straightforward. The GP Program Project Officer has put together packs with all the relevant forms and additional information that you may require. Please contact the GP Program Project Officer for a copy of this pack on (08) 7425 5045 or email: firstname.lastname@example.org.
- Insomnia Management Kit
The Insomnia Management Kit is designed to be used by GPs with patients who report sleep problems. The information in the Insomnia Management Kit will assist GPs in the assessment, diagnosis
andmanagement of patients presenting for the first time with a sleep problem. The Kit is composed of a series of fact sheets that can be downloaded for use with patients.
Accredited prescribers can obtain copies of the following resources by contacting the GP Program Project Officer on (08) 7425 5045 or email: email@example.com.
- The Methadone Handbook (Fourth Edition)
- Suboxone Sublingual film buprenorphine hydrochloride/naloxone hydrochloride: A Guide to Treatment
- Subutex: A Guide to Treatment
- National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn.
Understanding Suboxone prescribing
Prescribing buprenorphine with naloxone in film form (Suboxone®) for opioid dependence (non-accredited prescribing)
Buprenorphine with naloxone in film form (Suboxone®) has a perceived safer profile than methadone or buprenorphine (Subutex®) as a single agent. In South
Medical practitioners need to obtain a Section 18A Controlled Substances Act 1984 (SA) authority (PDF 185KB) from the SA Health Drugs of Dependence Unit prior to prescribing a drug of dependence for the treatment of opioid dependence. This authority must be obtained before treatment commences.
The Drugs of Dependence Unit can be contacted on 1300 652 584 Monday to Friday 9.00 am to 5.00 pm.
The following resources provide further information about prescribing this drug. Additional clinical resources are provided below.
- Fact Sheet: Buprenorphine/naloxone for opioid dependence: Important points to know about buprenorphine/naloxone (Suboxone®) (PDF 199KB)
- Buprenorphine/naloxone (Suboxone®) prescribing in South Australia (Microsoft PowerPoint presentation) (PPT 1683KB)
A medical practitioner must become accredited if they:
- wish to prescribe methadone liquid or buprenorphine as a single agent
- treat more than five patients at one time with buprenorphine with naloxone in film form.
- For more information go to GP Program - Accredited prescriber training and education page.